Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

BACKGROUND: Direct Antiviral Agents (DAAs) for HCV therapy represents a step ahead in the cure of chronic hepatitis C. Notwithstanding the promising results in several clinical trials, few data are available on adverse effects in real life settings. METHODS: We have evaluated 170 patients with persi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nappi, A., Perrella, A., Bellopede, P., Lanza, A., Izzi, A., Spatarella, M., Sbreglia, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297093/
https://www.ncbi.nlm.nih.gov/pubmed/28191032
http://dx.doi.org/10.1186/s13027-017-0119-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297093/
https://www.ncbi.nlm.nih.gov/pubmed/28191032
http://dx.doi.org/10.1186/s13027-017-0119-8

Ejemplares similares